Deregulated microRNAs in multiple myeloma

被引:45
作者
Benetatos, Leonidas [1 ]
Vartholomatos, George [2 ]
机构
[1] Univ Hosp Ioannina, Dept Hematol, Ioannina, Greece
[2] Univ Hosp Ioannina, Hematol Lab, Mol Biol Unit, Ioannina, Greece
关键词
microRNAs; multiple myeloma; target genes; regulatory networks; cancer; CELL DIFFERENTIATION; TARGETING MICRORNAS; NONCODING RNAS; IMPRINTED GENE; EXPRESSION; CANCER; MIRNAS; INHIBITION; BIOGENESIS; REPRESSION;
D O I
10.1002/cncr.26297
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs are short noncoding RNAS involved in gene expression regulation under physiological and pathological situations. They bind to mRNA of target genes and are potential regulators of gene expression at a post-transcription level through the RNA interference pathway. They are estimated to represent 1% to 2% of the known eukaryotic genome, and it has been demonstrated that they are involved in the pathogenesis of neurodegenerative diseases, cancer, metabolism disorders, and heart disease. MicroRNAs are known to act as tumor suppressors or oncogenes in cancer biology. The authors describe the current knowledge on microRNA involvement in regulatory pathways that characterize multiple myeloma pathogenesis gained from in vitro and in vivo studies. These small molecules interact with important factors such as p53, SOCS1, IGF-1, IGF-1R, vascular endothelial growth factor, NF-kappa B, and others. As such, microRNAs represent an attractive therapeutic target in the context of multiple myeloma interfering with the myeloma regulatory networks. Further studies are needed to better understand their role in myelomagenesis and their therapeutic potential. Cancer 2012;. (C) 2011 American Cancer Society.
引用
收藏
页码:878 / 887
页数:10
相关论文
共 70 条
  • [1] Adamia S, 2009, J CLIN ONCOL, V27
  • [2] microRNAs, RNA binding proteins and cancer
    Agami, Reuven
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (04) : 370 - 374
  • [3] Al Masri A, 2005, BLOOD, V106, p446A
  • [4] Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells
    Anastasiadou, Eleni
    Vaeth, Signe
    Cuomo, Laura
    Boccellato, Francesco
    Vincenti, Sara
    Cirone, Mara
    Presutti, Carlo
    Junker, Steffen
    Winberg, Gosta
    Frati, Luigi
    Wade, Paul A.
    Faggioni, Alberto
    Trivedi, Pankaj
    [J]. CANCER LETTERS, 2009, 284 (02) : 165 - 174
  • [5] Bakkus M, 2007, BLOOD, V110, p729A
  • [6] MicroRNAs: new regulators of immune cell development and function
    Baltimore, David
    Boldin, Mark P.
    O'Connell, Ryan M.
    Rao, Dinesh S.
    Taganov, Konstantin D.
    [J]. NATURE IMMUNOLOGY, 2008, 9 (08) : 839 - 845
  • [7] Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma
    Benetatos, Leonidas
    Dasoula, Aggeliki
    Hatzimichael, Eleftheria
    Georgiou, Ioannis
    Syrrou, Maria
    Bourantas, Konstantinos L.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03) : 171 - 175
  • [8] CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes
    Benetatos, Leonidas
    Hatzimichael, Eleftheria
    Dasoula, Aggeliki
    Dranitsaris, George
    Tsiara, Stavroula
    Syrrou, Maria
    Georgiou, Ioannis
    Bourantas, Konstantinos L.
    [J]. LEUKEMIA RESEARCH, 2010, 34 (02) : 148 - 153
  • [9] Bhagavathi S, 2010, ARCH PATHOL LAB MED, V134, P1276, DOI 10.1043/2009-0178-RS.1
  • [10] INNOVATION Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications
    Brown, Brian D.
    Naldini, Luigi
    [J]. NATURE REVIEWS GENETICS, 2009, 10 (08) : 578 - 585